UBS Group’s Artelo Biosciences, Inc. Warrant ARTLW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-4,697
Closed -$75 10344
2024
Q1
$75 Buy
+4,697
New +$100 ﹤0.01% 8881
2023
Q4
Sell
-100
Closed -$4 10209
2023
Q3
$4 Buy
+100
New +$5 ﹤0.01% 9312
2023
Q2
Sell
-687
Closed -$48 9970
2023
Q1
$48 Sell
687
-7,536
-92% -$469 ﹤0.01% 9346
2022
Q4
$329 Buy
+8,223
New +$685 ﹤0.01% 10243
2022
Q3
Sell
-289
Closed 11186
2022
Q2
$0 Sell
289
-1
-0.3% ﹤0.01% 11193
2022
Q1
$0 Buy
290
+90
+45% +$14 ﹤0.01% 11120
2021
Q4
$0 Sell
200
-4,177
-95% -$901 ﹤0.01% 10889
2021
Q3
$1K Sell
4,377
-190
-4% -$55 ﹤0.01% 9288
2021
Q2
$2K Buy
+4,567
New +$1.46K ﹤0.01% 9006

UBS Group's ARTLW Position: Q2 2024 in Review

UBS Group sold out of Artelo Biosciences, Inc. Warrant (ARTLW) in Q2 2024, closing a stake of 4,697 shares — an estimated $75 sold.

UBS Group first reported a position in ARTLW in Q2 2021 and held it in 9 quarters. The position peaked at $2K in Q2 2021. 0 funds tracked by Wall St. Rank hold ARTLW as of Q2 2024.

  • UBS Group reported no remaining Artelo Biosciences, Inc. Warrant position as of Q2 2024 after selling out during the quarter.
  • UBS Group sold 4,697 Artelo Biosciences, Inc. Warrant shares in Q2 2024, an estimated $75.
  • UBS Group first reported a position in Artelo Biosciences, Inc. Warrant in Q2 2021 and held it in 9 quarters.
  • UBS Group's Artelo Biosciences, Inc. Warrant position peaked at $2K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Artelo Biosciences, Inc. Warrant as of Q2 2024.

Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.